Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3883-3890

  Hoffmann, Katrin ^a   Shibo, Lin ^a   Xiao, Zhi ^a   Longerich, Thomas ^a   Büchler, Markus W ^a   Schemmer, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ABC proteins; Hepatocellular carcinoma; Liver resection; Multidrug resistance; Tyrosine kinase

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ABC TRANSPORTER; ABC TRANSPORTER A1; ADENOSINE TRIPHOSPHATE BINDING CASSETTE PROTEIN 2; ADENOSINE TRIPHOSPHATE BINDING CASSETTE PROTEIN 3; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; GLYCOPROTEIN P; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN TYROSINE KINASE; RAF PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM GRADING; NEOPLASM STAGING; P-GLYCOPROTEINS; PROGNOSIS; PROTEIN-TYROSINE KINASES; RAF KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 83055175095     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7): 2557-2576, 2007. (Pubitemid 46890874)
2. Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003. (Pubitemid 37518510)
3. Llovet JM, Fuster J and Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6): 1434-1440, 1999.
4. Llovet JM and Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1): S20-S37, 2008.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul JP, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib improves survival in hepatocellular carcinoma: results of a phase III randomized, placebo-controlled trial. J Clin Oncol 25(18S), 2007.
6. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26): 4293-4300, 2006. (Pubitemid 46630787)
7. Ganne-Carrie N and Trinchet JC: Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 16(3): 275-281, 2004. (Pubitemid 38368370)
8. Villanueva A, Toffanin S and Llovet JM: Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol 20(4): 444-453, 2008.
9. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2(1): 48-58, 2002. (Pubitemid 37328807)
10. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H and Trauner M: Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 25(2): 367-379, 2005.
11. Bonin S, Pascolo L, Croce LS, Stanta G and Tiribelli C: Gene expression of ABC proteins in hepatocellular carcinoma, perineo-plastic tissue, and liver diseases. Mol Med 8(6): 318-825, 2002.
12. Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, Nakagawa K, Shimizu H, Yokosuka O and Nakajima N: Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 78(2): 110-115, 2001.
13. Soini Y, Virkajarvi N, Raunio H and Paako P: Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 49: 470-473, 1996. (Pubitemid 26226536)
14. Barancik M, Bohacova V, Kvackajova J, Hudecova S, Krizanova O and Breier A: SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 14(1): 29-36, 2001. (Pubitemid 32655412)
15. Yang JM, Sullivan GF and Hait WN: Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem Pharmacol 53(11): 1597-1604, 1997. (Pubitemid 27356088)
16. Yang JM, Vassil AD and Hait WN: Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 60(4): 674-680, 2001. (Pubitemid 32900248)
17. Hoffmann K, Xiao Z, Franz C, Mohr E, Schultze D, Serba S, Büchler MW amd Schemmer P: Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in experimental hepatocellular carcinoma. Under review.
18. Hoffmann K, Franz C, Xiao Z, Mohr E, Serba S, Büchler MW and Schemmer P: Sorafenib modulates multidrug resistance in experimental hepatocellular carcinoma. Anticancer Res 30(11): 4503-4508, 2010.
19. World Medical Association Declaration of Helsinki. Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects, Adopted by the 18th World Medical Assembly Helsinki, Finland, June 1964, amended by 48th General Assembly, Somerset West, South Africa, [http://wwwwmanet/e/policy/pdf/ 17cpdf] 1996.
20. Bosch FX, Ribes J, Cleries R and Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9(2): 191-211, 2005.
21. Pearson G, Robinson F, Beers GT, Xu BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22(2): 153-183, 2001. (Pubitemid 32458157)
22. Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M, Matsuda Y, Nomoto M and Aoyagi Y: Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 24: 432-436, 2004. (Pubitemid 40484556)
23. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N and Hori M: Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27(4): 951-958, 1998. (Pubitemid 28160479)
24. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW and Baba HA: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48(1): 83-90, 2008. (Pubitemid 350191996)
25. Wang X, Martindale JL and Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275(50): 39435-39443, 2000. (Pubitemid 32058968)
26. Azzariti A, Porcelli L, Simone GM, Quatrale AE, Colabufo NA, Berardi F, Perrone R, Zucchetti M, D'Incalci M, Xu JM and Paradiso A: Tyrosine kinase inhibitors and multidrug-resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol 65(2): 335-346, 2010.
27. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B and Keri G: Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochem Biophys Acta 1587(2-3): 318-325, 2002. (Pubitemid 34655800)
28. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Kéri G, Orfi L, Német K and Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65(6): 1485-1495, 2004. (Pubitemid 38668306)
29. Guan J, Chen XP, Zhu H, Luo SF, Cao B and Ding L: Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J Gastroenterol 10(23): 3522-3527, 2004. (Pubitemid 39549558)
30. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ and Keppler D: Expression of the multidrug-resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 94(4): 492-499, 2001.
31. Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goni S, Santamaria M, Prieto J and Avila MA: The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med 234(7): 713-725, 2009.
32. Breuhahn K, Longerich T and Schirmacher P: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25(27): 3787-3800, 2006. (Pubitemid 43980474)
33. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM and Thorgeirsson SS: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130(4): 1117-1128, 2006.
34. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 6(7): 2092-2102, 2007. (Pubitemid 47052500)
35. Garcia R, Franklin RA and McCubrey JA: EGF induces cell motility and multidrug-resistance gene expression in breast cancer cells. Cell Cycle 5(23): 2820-2826, 2006. (Pubitemid 44901745)